Actionable news
0
All posts from Actionable news
Actionable news in ARRY: Array BioPharma Inc.,

​Bristol-Myers BMY meets melanoma endpoint; Merck MRK clinical hold issued on KEYTRUDA multiple myeloma trials

Price and Volume Movers

Bristol-Myers Squibb Company (NYSE:BMY) announced that its Phase 3 trial (CheckMate -238) of Opdivo in patients with late stage melanoma who are at high risk of recurrence following surgery, met its primary endpoint following an interim analysis, demonstrating superior recurrence-free survival (RFS) compared to Yervoy. These data will be submitted for presentation at an upcoming medical conference.

Merck (NYSE:MRK) announced that the FDA has placed a clinical hold on KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023, three combination studies of KEYTRUDA, in trials for multiple myeloma. This decision follows a review of data that indicate that the risks of KEYTRUDA plus pomalidomide or lenalidomide outweigh any potential benefit for patients with multiple myeloma. This clinical hold does not apply to other studies with KEYTRUDA. Shares are currently trading down 1% to $64.16 in the after-hours session.

Array BioPharma (Nasdaq: ARRY) announced the submission of two New Drug Applications (NDAs) to...


More